Siegfried Holding, a Switzerland-based life-sciences company, has increased its guidance for 2023 following higher sales performance in the first half of the year. The growth was primarily driven by its drug-substances business, although earnings were slightly lower due to increased costs.
The company now expects full-year sales growth at a constant currency rate in the mid single percentage digits, exceeding its previous forecast of low-to-mid single digits. Furthermore, Siegfried anticipates that its core earnings before interest, taxes, depreciation, and amortization (EBITDA) margin will be above 20%, as opposed to the previous expectation of a margin at or above 20%.
During the first half of the year, Siegfried generated net sales amounting to 607.1 million Swiss francs ($689.8 million), reflecting a growth of 6.8% in local currencies compared to the same period last year. While there was a decline in its drug-products segments, this was offset by increased sales in the drug-substance division.
Despite the overall positive sales performance, net profit decreased from CHF62.7 million to CHF55.2 million. Additionally, core EBITDA fell by 3.4% to CHF125.7 million, resulting in a decline in the margin from 22.2% to 20.7%.
For more information, please contact Adria Calatayud.
Our Latest News
Long-term Treasury bond ETFs face declines as Goldman Sachs predicts potential rate cuts by the Federal Reserve, impacting investors.
New Street Research report highlights the underestimation of AI revenue prospects for Nvidia, Broadcom, and Arista by Wall Street analysts. The report suggests...
Unifi, a fiber manufacturer, reports a loss of $15.3 million and a decrease in sales in the fourth quarter. Factors such as weak demand and lower sales volumes...